MedTrace Logo

Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis

NCT03586063 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 465

Last updated 2018-07-13

No results posted yet for this study

Summary

To describe Gonadotropin-Releasing Hormone agonists (GnRH-a) treatment effectiveness on reduction of internal genital endometriosis symptom - menorrhagia - in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3,75 mg - assessment performed six months after the last injection.

Conditions

  • Internal Endometriosis

Interventions

OTHER

Data collection

This is a non-interventional (observational) national multicentre prospective study. Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days. The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Study Director · Ipsen

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-03
Primary Completion
2014-12-24
Completion
2014-12-24

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03586063 on ClinicalTrials.gov